AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for HER2 Positive Solid Tumor

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors NCT07318805Phase 113 sites๐Ÿ“ Duarte๐Ÿ“ Grand Rapids๐Ÿ“ Long Island City Pfizer ยท Tests: PF-08032562, Fulvestrant, Cetuximab, Fluorouracil, Oxaliplatin IKS014 in Advanced Solid Tumors That Express HER2 NCT05872295Phase 113 sites๐Ÿ“ Newport Beach๐Ÿ“ Boston๐Ÿ“ Nashville Iksuda Therapeutics Ltd. ยท Tests: IKS014 EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC NCT07617805Phase 1, Phase 21 site๐Ÿ“ Shenzhen Beijing Biotech ยท Tests: EGFR/HER2 Dual-Target CAR-NK Cells, Fludarabine, Cyclophosphamide Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors NCT06658951NA1 site๐Ÿ“ Zhengzhou UTC Therapeutics Inc. ยท Tests: Anti-HER2 CAR-T cells Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors NCT07288359Phase 1, Phase 216 sites๐Ÿ“ Atlanta๐Ÿ“ Nashville๐Ÿ“ San Antonio Novartis Pharmaceuticals ยท Tests: GVV858, Fulvestrant, Letrozole A Trial of HRS-6209-205 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Combination Therapy in Subjects With HR-Positive/HER2-Negative Cancer NCT07358377Phase 16 sites๐Ÿ“ Bowral๐Ÿ“ Sydney๐Ÿ“ Sydney Atridia Pty Ltd. ยท Tests: HRS-6209 Capsules and fulvestrant injection A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors NCT06503783Phase 12 sites๐Ÿ“ Harbin๐Ÿ“ Shanghai Sichuan Baili Pharmaceutical Co., Ltd. ยท Tests: BL-M17D1 A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors NCT07383506Phase 112 sites๐Ÿ“ Scottsdale๐Ÿ“ Los Angeles๐Ÿ“ Palo Alto Cogent Biosciences, Inc. ยท Tests: CGT6297 Gene Therapy for HER-Positive Cancer (SENTRY-HER2) NCT07192432Phase 1, Phase 211 sites๐Ÿ“ Los Angeles๐Ÿ“ Denver๐Ÿ“ Jacksonville Vironexis Biotherapeutics Inc. ยท Tests: Dose Level 1, VNX-202, Dose Level 2, VNX-202, Dose Level 3, VNX-202, Dose Level 4, VNX-202 Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors NCT05985655Phase 1, Phase 215 sites๐Ÿ“ Los Angeles๐Ÿ“ Grand Rapids๐Ÿ“ New York Exscientia AI Ltd., a wholly owned subsidiary of Recursion โ€ฆ ยท Tests: GTAEXS617, SoC HF50 in HER-2 Positive and Low-expression Advanced Solid Tumors NCT06822998EARLY Phase 11 site๐Ÿ“ Chengdu HighField Biopharmaceuticals Corporation ยท Tests: HF50 Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor NCT05523947Phase 1, Phase 219 sites๐Ÿ“ Boston๐Ÿ“ Nashville๐Ÿ“ Adelaide Yuhan Corporation ยท Tests: YH32367 A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer NCT04872166Phase 16 sites๐Ÿ“ Lake Mary๐Ÿ“ Sarasota๐Ÿ“ Cincinnati Edgewood Oncology Inc. ยท Tests: BTX-A51 A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors NCT06500052Phase 11 site๐Ÿ“ Guangzhou Sichuan Baili Pharmaceutical Co., Ltd. ยท Tests: BL-M17D1 A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors NCT06669975Phase 1, Phase 23 sites๐Ÿ“ Macquarie๐Ÿ“ Bedford Park๐Ÿ“ Perth AP Biosciences Inc. ยท Tests: AP402 (Part 1 Dose esclation), AP402 (Part 2 Dose Expansion) Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer NCT07589517Phase 1, Phase 21 site๐Ÿ“ Shenzhen Beijing Biotech ยท Tests: EB-DUO-CAR-NK-CEA/GCC, Lymphodepletion HER-2 B Cell Peptide Vaccine NCT06414733Phase 11 site๐Ÿ“ Indianpolis Pravin T.P Kaumaya ยท Tests: Combination of MVF-HER-2 (597-626) and MVF-HER-2 (266-296) emulsified with ISA 51 Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors NCT07287917Phase 1, Phase 220 sites๐Ÿ“ Tucson๐Ÿ“ La Jolla๐Ÿ“ Los Angeles Aminex Therapeutics, Inc. ยท Tests: AMXT 1501 Dicaprate, DFMO, Fulvestrant, Capivasertib, Pembrolizumab A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors NCT07767474Phase 1, Phase 26 sites๐Ÿ“ Fort Worth๐Ÿ“ Houston๐Ÿ“ San Antonio Antares Therapeutics, Inc ยท Tests: ATX-898, ATX-898, ATX-898, ATX-898, ATX-898 To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer NCT06504732Phase 2, Phase 32 sites๐Ÿ“ Harbin๐Ÿ“ Shenyang SUNHO๏ผˆChina๏ผ‰BioPharmaceutical CO., Ltd. ยท Tests: IAH0968, Trastuzumab Injection A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor NCT07612891Phase 1, Phase 21 site๐Ÿ“ Shanghai Shenzhen Ionova Life Sciences Co., Ltd. ยท Tests: INV-6452 A Study of D3L-001 as Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors NCT05957536Phase 19 sites๐Ÿ“ Stanford๐Ÿ“ Boston๐Ÿ“ New York D3 Bio (Wuxi) Co., Ltd ยท Tests: D3L-001 Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors NCT06726148Phase 1, Phase 233 sites๐Ÿ“ Los Angeles๐Ÿ“ Fort Myers๐Ÿ“ Boston Novartis Pharmaceuticals ยท Tests: ECI830, ribociclib, fulvestrant TGW211 for Click-Cleavable Imaging in HER2-Positive Cancers. NCT07009184EARLY Phase 11 site๐Ÿ“ Nijmegen Radboud University Medical Center ยท Tests: [111In]In-DOTA-TCO-trastuzumab, Small molecule tetrazine trigger component A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2-Positive/Negative Breast Cancer and Other Solid Tumors NCT05461768Phase 17 sites๐Ÿ“ Fuzhou๐Ÿ“ Dongguan๐Ÿ“ Guangdong Sichuan Baili Pharmaceutical Co., Ltd. ยท Tests: BL-M07D1 HER2 Targeted HypoSti.CAR-T Cells in HER2 Positive Advanced Solid Tumors NCT05681650Phase 1, Phase 21 site๐Ÿ“ Beijing Chinese PLA General Hospital ยท Tests: HypoSti.CAR-HER2 T cells, Albumin-bound paclitaxel, Cyclophosphamide, Fludarabine A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors NCT06031584Phase 1, Phase 21 site๐Ÿ“ Beijing Sichuan Baili Pharmaceutical Co., Ltd. ยท Tests: BL-M07D1 Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors NCT06950086Phase 1, Phase 22 sites๐Ÿ“ Shanghai๐Ÿ“ Shanghai TYK Medicines, Inc ยท Tests: TYK-00540 HEAT Trial (HER2 Antibody Therapy With Lutetium-177) NCT06824155EARLY Phase 15 sites๐Ÿ“ Kingswood๐Ÿ“ Macquarie Park๐Ÿ“ Wollongong Radiopharm Theranostics, Ltd ยท Tests: 177Lu-RAD202 Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) NCT05579366Phase 1, Phase 266 sites๐Ÿ“ Phoenix๐Ÿ“ Tucson๐Ÿ“ Los Angeles Genmab ยท Tests: Rina-S, Carboplatin, Bevacizumab, Pembrolizumab, Erythromycin
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy